| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:47 | Fresenius and WuXi team up in 37-strong biosimilar development deal | ||
| 11:46 | Pelthos and Castle Creek plan merger to target skin diseases | ||
| 10:46 | Inovio's Voceryq receives FDA accelerated approval for RRP | ||
| Fr | Casgevy gains UK label expansion for younger patient population | ||
| Fr | Eli Lilly's tirzepatide outperforms big pharma companies in Q3 | ||
| Fr | Glenmark opens Allentown distribution hub in US | ||
| Fr | Dren Bio raises $350m for dibotatug clinical development | ||
| Do | RFK Jr backs compounding of six unapproved peptides in new policy | ||
| Do | UK Budget light on life sciences but more doors open for biotech startups | ||
| Do | Enthorin and Rumi sign agreement for FXS therapy | ||
| Do | Formation Bio launches $600m drug development fund | ||
| Mi | Ferring bets on Gameto's reproductive health solution through $1.38bn takeover | ||
| Mi | Astellas fortifies immuno-oncology pipeline on $1.3bn Audax licensing deal | ||
| Mi | FDA grants orphan drug status to Octant's OCT-980 for RP | ||
| Mi | Arrowhead gains UK marketing authorisation for Redemplo | ||
| Mi | Anthropic plots IPO amid ongoing foray into drug development | ||
| Di | Pfizer's prostate cancer combo moves to earlier line on expanded US approval | ||
| Di | Regeneron agrees to $270m extension to supply Ebola medicine in US | ||
| Di | China's NMPA accepts Innovent application for sintilimab combo | ||
| 26.10. | UK biotech poised for record VC year after maintaining recovery momentum | ||
| 26.10. | Lunit and Summit to evaluate pathology platform for tumour analysis | ||
| 26.10. | Pathos AI completes $237m Series E round to expand oncology pipeline | ||
| 23.10. | US targets Chinese biotech investment, but licensing deals remain exempt | ||
| 23.10. | Gilead spends $1.28bn on PepStar's potential Icotyde rival | ||
| 23.10. | Boehringer and Microsoft collaborate to explore AI in clinical research |